Ubs Asset Management Americas Inc Cullinan Oncology, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 80,353 shares of CGEM stock, worth $670,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80,353
Previous 91,792
12.46%
Holding current value
$670,144
Previous $1.12 Million
45.62%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CGEM
# of Institutions
154Shares Held
68.5MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$63.8 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$48 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$32.2 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$29.6 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$28.5 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $380M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...